The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Purchase price of US $ 1.5 billion upfront and up to USD 500 million in success-based milestone payments
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
Subscribe To Our Newsletter & Stay Updated
